Delayed generation of functional virus-specific circulating T follicular helper cells correlates with severe COVID-19

Longitudinal sampling during SARS-CoV-2 infection

In total, 49 adults with PCR-confirmed SARS-CoV-2 infection were enrolled in the study. Longitudinal blood samples were collected multiple times during acute, symptomatic disease as well as during convalescence (median 3 and 8 months from symptom onset) (Figure 1a and b). Identical samples from 20 age- and gender-matched pre-pandemic healthy controls (HCs) were used as baseline comparison (Figure 1a and Table 1). Disease severity was assessed daily in admitted patients and classified according to the respiratory domain of the sequential organ failure assessment (SOFA) score, with additional levels for non-admitted patients as mild cases. Patients were grouped based on their peak disease severity, which may differ from disease severity at time of sampling (Figure 1b). In this study, patients with mild, moderate and severe peak COVID-19 disease severity are hereafter referred to as mild, moderate and severe patients. Medical records from patient groups across disease severity were analysed (Table 2). The distribution of age varied significantly across peak disease severity groups of COVID-19 patients (P<0.05), as did male sex (P<0.01) and the BMI (P<0.01) (Table 2), similar to what has been observed in other COVID-19 patient cohorts ^1,30.

• Download figure
• Open in new tab

Figure 1. Longitudinal frequency and activation of cTfh cells in COVID-19 patients across disease severity from acute disease up to 8 months convalescence.

(a) Overview of study cohort (n=75), and (b) the timeline of longitudinal sampling. Patients are grouped based on peak disease severity, including mild (green), moderate (orange) and severe (red). Individual patients are color-coded based on daily disease severity. PaO2 is expressed in kPa. (c) Gating strategy to identify cTfh cells in PBMCs by flow cytometry. From single, live CD3+ CD4+ T cells, memory CD4+ T cells were identified as CD45RA-. From memory CD4+ T cells, cTfh cells were identified as CXCR5+ cells. cTfh subsets were identified as cTfh1 (CXCR3+ CCR6−), cTfh2 (CXCR3− CCR6−) and cTfh17 (CXCR3− CCR6+). Activated cTfh and its subsets were identified with ICOS+ CD38+ expressing. Patients are grouped based on peak disease severity, including mild (green), moderate (orange) and severe (red). (d) Bar charts show the frequency of bulk and activated cTfh, cTfh1, cTfh2 and cTfh17 cells from COVID-19 patients with acute disease (Acute), 3 months convalescence (3 months) and 8 months convalescence (8 months) with median. Dots are individual samples color-coded according to peak disease severity. Dotted lines show the median frequency with 95% Cl (grey area) of pre-pandemic healthy controls. X axis shows the number of patients in each bar. During acute disease, 9, 22 and 33 individual samples from 9 mild, 14 moderate and 18 severe patients respectively were analysed and Generalized Estimating Equations (GEE) was used to account for the intra-person correlations inherent to repeated measures and assess statistically significant differences at p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. During 3 and 8 months convalescence, only 1 sample from each patient was analysed and Kruskal-Wallis with Dunn’s multiple comparisons test was used to assess statistically significant differences at p<0.05. ** p<0.01, *** p<0.001, **** p<0.0001.

cTfh cell abundance and activation are altered in severe COVID-19

To understand the longitudinal dynamics of cTfh cell characteristics in COVID-19 patients across disease severity, from acute disease to convalescence, PBMCs from 41 patients and 20 healthy controls were analysed by flow cytometry (Supplementary Table 1). cTfh cells were identified as CXCR5+ memory CD4+ T cells and cTfh cell activation was determined by expression of CD38 and ICOS ¹⁶ (Figure 1c). cTfh cells were further differentiated based on CCR6 and CXCR3 expression to identify cTfh1 (CXCR3+, CCR6−), cTfh2 (CXCR3−, CCR6−) and cTfh17 (CXCR3−, CCR6+) cells (Figure 1c). Total cTfh cell frequencies were significantly lower in moderate and severe patients compared to mild during acute disease but normalized to similar levels as observed in healthy controls (dotted line) during convalescence (Figure 1d). During acute disease, frequencies of cTfh1 and cTfh17 but not cTfh2 cells were significantly lower in severe patients than in mild patients, while there was no significant difference in frequency of cTfh1, cTfh2 and cTfh17 cells in patients across disease severity at the 3 and 8 months convalescence time points (Figure 1d). In contrast, frequencies of activated CD38+ ICOS+ cTfh cells were significantly higher in severe and moderate patients than in mild patients during acute disease and normalised during both 3 and 8 months convalescence (Figure 1d). When looking at cTfh subsets, there was no statistically significant differences in the frequency of activated cTfh1, cTfh2 or cTfh17 cells during acute disease (Figure 1d). These results show that as disease severity increased during acute SARS-CoV-2 infection, cTfh cells were lower in frequency but a higher proportion were activated, suggesting that cTfh cell frequency and activation associate with disease severity in COVID-19 patients during acute disease.

Frequencies of activated cTfh cells correlate with SARS-CoV-2 plasma antibody level and blood plasmablast frequencies in patients during acute COVID-19

To assess whether cTfh cell patterns associate with the humoral immune response, longitudinal plasma antibody levels against SARS-CoV-2 spike and RBD by ELISA as well as the blood plasmablast (PB) frequency were analyzed by flow cytometry (Supplementary Figure 1 and Supplementary Table 2). In line with previous reports from us and others ^31–33, we found that plasma IgA and IgG against SARS-CoV-2 spike and RBD proteins increased with increasing disease severity, during both acute disease and 3 months convalescence (Figure 2a). Furthermore, plasma IgA against SARS-CoV-2 RBD and plasma IgG against SARS-CoV-2 spike and RBD positively correlated with the frequency of activated cTfh cells during acute disease (Figure 2b). Frequencies of activated cTfh1, cTfh2 and cTfh17 cells positively correlated with plasma spike and RBD IgG, and frequencies of activated cTfh1 and cTfh17 cells positively correlated with plasma RBD IgA (Figure 2c). Frequencies of blood plasmablast in severe and moderate COVID-19 patients were significantly higher than that in mild patients during acute disease and normalised to frequencies comparable to healthy controls during convalescence (Figure 2d). During acute disease, frequencies of blood plasmablast in patients across disease severity positively correlated with the frequency of activated cTfh cells in the same samples (Figure 2e), including cTfh1, cTfh2 and cTfh17 cells (Figure 2f).

• Download figure
• Open in new tab

Figure 2. Longitudinal titers of plasma immunoglobulins against SARS-CoV-2 spike and RBD and frequency of blood plasmablast (PB) in COVID-19 patients across disease severity from acute disease up to 8 months convalescence.

(a) Titers of plasma IgA and IgG against SARS-CoV-2 spike and RBD were tested by ELISA and bar charts show the OD value with median. During acute infection, 9, 22 and 33 individual samples from 9 mild, 14 moderate and 18 severe patients respectively were analysed and Generalized Estimating Equations (GEE) was used to account for the intra-person correlations inherent to repeated measures and assess statistically significant differences at p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. During 3 and 8 months convalescence, only 1 sample from each patient was analysed and Kruskal-Wallis with Dunn’s multiple comparisons test was used to assess statistically significant differences at p<0.05. ** p<0.01, *** p<0.001, **** p<0.0001. One severe patient displayed IgA deficiency over time was excluded in all IgA analysis. (b-c) Spearman correlation for plasma immunoglobulins against the spike and RBD versus frequency of (b) activated cTfh and (c) activated cTfh subsets during acute disease. 9, 14 and 18 individual samples from 9 mild, 14 moderate and 18 severe patients were analysed. For patients with longitudinal acute samples, data from the earliest sample was involved as representative in Spearman correlation analysis. (d) Frequency of plasmablast out of CD19+ B cells from COVID-19 patients is shown by bar chats with median, and the dotted lines show the median frequency with 95% Cl (grey area) of healthy controls. Dots are individual samples color-coded according to peak disease severity. X axis shows the number of patients in each bar. Only 1 individual sample from each patient was analysed during both acute disease and convalescence. Kruskal-Wallis with Dunn’s multiple comparisons test was used to consider all statistically significant at p<0.05. ** p<0.01, *** p<0.001, **** p<0.0001. (e-f) Spearman correlation for frequency of plasmablast versus frequency of (e) activated cTfh and (f) activated cTfh subsets during acute disease. 9, 10 and 9 individual samples from 9 mild, 10 moderate and 9 severe patients were analysed so that only 1 individual sample from each patient was analysed during acute disease.

SARS-CoV-2 spike- and RBD-specific cTfh cell activation correlate with plasma antibody levels and blood plasmablast frequencies during acute COVID-19

Next, to mechanistically test whether cTfh cells are indeed reactive to SARS-CoV-2 antigens, we next measured the frequency of SARS-CoV-2 spike and RBD-specific cTfh cells in patients across disease severity from acute infection to convalescence. PBMCs from 41 patients or 20 healthy controls were stimulated with SARS-CoV-2 spike or RBD proteins, or with BSA or SEB as negative and positive controls, respectively. After 20 hours of stimulation, cTfh cells from COVID-19 patients but not cTfh cells from pre-pandemic healthy controls upregulated the activation markers CD25 and CD134 in response to the viral proteins (Figure 3a and Supplementary Table 3). We found that the frequencies of both spike- and RBD-specific cTfh cells were significantly higher in severe and moderate patients than that in mild patients during acute infection (Figure 3b). This pattern held true also during convalescence; both spike- and RBD-specific cTfh cells were detectable in blood of former COVID-19 patients, albeit at lower levels than during acute illness (Figure 3b), consistent with previous studies ^24–26. Again, individuals who recovered from severe COVID-19 displayed higher frequencies of spike and RBD-specific cTfh cells even at 8 months of convalescence compared to patients who had recovered from mild disease (Figure 3b). Frequencies of spike and RBD-specific cTfh cells positively correlated with frequencies of activated cTfh cells during acute infection (Supplementary Figure 2), indicating that the frequency of activated cTfh cells may reflect ongoing immune reactions against the antigen or virus. During acute disease, the frequencies of spike- and RBD-specific cTfh cells positively correlated with both plasma antibody levels to the same viral proteins (Figure 3c) as well as to the blood plasmablast frequency (Figure 3d). Cytokines produced by PBMCs in response to spike and RBD were measured by Luminex, including IL-21, IFNγ, IL-4 and IL-17 (Figure 3e).

• Download figure
• Open in new tab

Figure 3. Longitudinal frequency of SARS-CoV-2 spike and RBD-specific cTfh in COVID-19 patients across disease severity from acute disease up to 8 months convalescence.

PBMCs from COVID-19 patients or healthy controls were cultured and stimulated with 5µg/mL SARS-CoV-2 spike or RBD protein for 20 hours, then cells were tested by flow cytometry and cytokines in supernatant were determined by Luminex. Cells were also exposed to 5µg/mL BSA protein or 0.1µg/ mL SEB as negative and positive controls respectively. (a) Representative example with gating strategy to identify SARS-CoV-2 spike and RBD-specific cTfh by flow cytometry. From single, live CD3+ CD4+ CD45RA− CXCR5+ cTfh cells, CD25+ CD134+ cells were determined as virus-specific cTfh. (b) Bar charts show the median frequency of SARS-CoV-2 spike and RBD-specific cTfh from acute disease up to 8 months convalescence with median. Dots are individual samples color-coded according to peak disease severity. Dotted lines show the median frequency with 95% Cl (grey area) of healthy controls. During acute disease, 9, 22 and 33 individual samples from 9 mild, 14 moderate and 18 severe patients respectively were analysed and Generalized Estimating Equations (GEE) was used to account for the intra-person correlations inherent to repeated measures and assess statistically significant differences at p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. During 3 and 8 months convalescence, only 1 sample from each patient was analysed and Kruskal-Wallis with Dunn’s multiple comparisons test was used to assess statistically significant differences. (c-d) Spearman correlation for frequency of virus-specific cTfh versus (c) titers of plasma immunoglobulins against the spike and RBD, and versus (d) frequency of blood plasmablast during acute disease. For patients with longitudinal acute samples, data from the earliest sample was involved as representative in Spearman correlation analysis. (e) Bar charts show the median concentration of IL-21, IFN, IL-4, IL-17 cytokines in supernatants of SARS-CoV-2 spike and RBD protein stimulated PBMCs from COVID-19 patients with acute disease. Dotted lines show the median concentration of cytokines with 95% Cl (grey area) in supernatants from SARS-CoV-2 spike and RBD protein stimulated PBMCs from healthy controls. 9, 22 and 33 individual samples from 9 mild, 14 moderate and 18 severe patients respectively were analysed and Generalized Estimating Equations (GEE) was used to account for the intra-person correlations inherent to repeated measures and assess statistically significant differences. (f-g) Heatmap summarizing the interrelationship between characteristics of cTfh cells and (f) clinical parameters, and (g) levels of plasma cytokines/chemokines from COVID-19 patients with acute disease. 9, 22 and 33 individual samples from 9 mild, 14 moderate and 18 severe patients respectively were analysed and repeated measures correlations were calculated.

Furthermore, PBMCs isolated from severe COVID-19 patients at the acute phase of disease produced higher levels of IL-21, IFNγ, IL-4 and IL-17 in response to spike and RBD, than PBMCs from mild patients (Figure 3e). We also found the level of plasma CXCL13 from severe COVID-19 patients was significantly higher than mild patients during acute infection (Supplementary Figure 3). In addition, we found that the frequencies of activated and virus-specific cTfh cells in COVID-19 patients with acute disease were positively correlated with clinical parameters including age, CCI and peak disease severity (Figure 3f). These data suggest that severe COVID-19 patients display a more robust cTfh cell response with higher level of activation markers expression and cytokines production than mild COVID-19 patients in response to SARS-CoV-2 protein, which was associated with higher frequencies of blood antibody secreting cells and antibody titers against SARS-CoV-2 virus in severe COVID-19 patients compared to mild patients. Plasma cytokines and chemokines of COVID-19 patients with acute disease were analysed using a proximity extension assay (Olink Proteomics) (Figure 3g). Furthermore, we found that that frequencies of activated cTfh especially cTfh1 and cTfh2 cells, and frequencies of virus-specific cTfh cells were positively correlated with acute disease plasma levels of TNF protein family members including TNFRSF9, TNFβ, TRAIL and TWEAK, but negatively correlated with IL-6 (Figure 3g). Our data suggest that cytokines responses induced by SARS-CoV-2 might affect generation of functional virus-specific cTfh cells against COVID-19.

cTfh cells isolated from severe COVID-19 patients support plasmablast differentiation and antibody production in vitro more effectively than cTfh cells from mild patients

To confirm the functional capacity of cTfh cells from COVID-19 patients to help B cell differentiation and antibody production, and compare the functional cTfh cell capacity in severe and mild COVID-19 patients, we isolated cTfh and non-cTfh (CD3+ CD4+ CD45RA− CXCR5−) cells from 4 severe and mild COVID-19 patient samples from the acute stage of disease as well as from 4 healthy controls (Supplementary Table 4 and 5). cTfh and non-cTfh cells were co-cultured with autologous memory or naïve B cells, respectively at a T cell: B cell ratio of 1:1, in the presence of Staphylococcal enterotoxin B (SEB) to enhance the T-B cell interaction (Supplementary figure 4 and Figure 4a). After 6 days co-culture of memory B cells and after 9 days co-culture of naïve B cells with either cTfh or non-cTfh cells, the number of live B cells (Figure 4b-c) as well as the frequency of differentiated CD38+ CD27+ plasmablasts (Figure 4d) in the co-cultures was determined by flow cytometry. cTfh cells, but not non-cTfh cells, efficiently supported both memory and naïve B cell survival and differentiation into plasmablasts (Figure 4b-c). Importantly, cTfh cells isolated from severe COVID-19 patients more efficiently supported memory and naïve B cell survival as well as plasmablast differentiation, as compared to cTfh cells isolated from mild COVID-19 patients or from healthy controls (Figure 4c-d). Next, the concentration of total IgA and IgG in the co-culture supernatants was measured by ELISA. (Figure 4e) IgA and (Figure 4f) IgG were detectable in cTfh co-cultures with both memory B cells and naïve B cells and immunoglobulin concentrations were significantly higher in co-cultures with cells isolated from severe COVID-19 patients compared to mild patients or healthy controls. In contrast, IgA or IgG were not detectable in supernatants from non-cTfh cell co-cultures (Figure 4e-f). In line with cTfh cell functionality, IL-21 was only detectable in cTfh co-cultures (Figure 4g). Again, IL-21 supernatant concentrations were higher in co-cultures with cells isolated from severe COVID-19 patients compared to mild patients or healthy controls (Figure 4g), suggesting that the functionality of overall cTfh cells is more potent in severe compared to mild COVID-19.

• Download figure
• Open in new tab

Figure 4. cTfh isolated from severe COVID-19 patients with acute disease support B cells differentiation and antibody production more efficiently than that from mild COVID-19 patients.

(a) Blood cTfh, non-cTfh, memory B and naïve B cells were isolated from four severe and mild COVID-19 patients with acute disease, as well as four healthy donors. cTfh or non-cTfh cells were cultured with autologous memory B cells for 6 days, or with autologous naïve B cells for 9 days respectively. (b) Representative example with gating strategy to identify (left) memory B cell and (right) naïve B cell differentiation. (c) Bar charts show the number of live B cells in (left) cTfh/non-cTfh co-cultured with memory B cells and (right) cTfh/non-cTfh co-cultured with naive B cells. (d) Bar charts show the frequency of plasmablast in cTfh-memory/naïve B cell co-cultured. (e-f) Bar charts show the concentration of (e) IgA and (f) IgG in supernatant from cTfh/non-cTfh co-cultured with (left) memory B cells and (right) naive B cells. (g) Bar charts show the concentration of IL-21 in supernatant from cTfh/non-cTfh co-cultured with (left) memory B cells and (right) naive B cells. In e-g ND means not detectable. One-Way ANOVA was used to consider statistically significant at p<0.05. ** p<0.01, *** p<0.001, **** p<0.0001.

Appearance of SARS-CoV-2-specific cTfh cells is delayed in severe COVID-19 patients compared to patients with mild and moderate disease

It is counter-intuitive that individuals with the highest frequencies and most functional cTfh cells as well as the highest antibody levels directed to the virus are the most severely ill patients. To resolve this paradox, we next took advantage of the fact that we had longitudinal samples during acute disease after less than two weeks of symptom onset, 2-3 weeks, 3-4 weeks as well as more than 4 weeks after symptom onset in the different disease severity groups (Supplementary Figure 5). We found that very early after symptom onset (< 2 weeks), in individuals who already displayed or later developed severe disease, not only the frequencies of total cTfh cells (Figure 5a), but also the frequency of activated cTfh cells (Figure 5b) and importantly the frequencies of spike- and RBD-specific cTfh cells (Figure 5c) were significantly lower than in individuals who maintained/developed mild or moderate COVID-19. As the disease progressed, severe patients presented with increased frequencies of activated cTfh cells (Figure 5b) and SARS-CoV-2 spike- and RBD-specific (Figure 5c) cTfh cells to similar or higher levels than observed in mild and moderate patients after 4 weeks after symptom onset. These data indicate that appearance of activated and SARS-CoV-2-specific cTfh cells was delayed in severe patients compared to moderate and mild patients during acute disease, potentially pointing to impaired generation of virus-specific cTfh cells early during infection. However, there was no significant difference in frequencies of SARS-CoV-2 spike- and RBD-specific CXCR5− memory CD4 T cells (non-cTfh cells) between severe and mild COVID-19 patients during early infection (Figure 5d), suggesting that the delayed appearance of virus-specific memory CD4 T cells was restricted to the cTfh cell compartment.

• Download figure
• Open in new tab

Figure 5. Delayed emergence of activated and virus-specific cTfh cells correlated with delayed emergence of high avidity and neutralization plasma antibodies in severe COVID-19 patients compared to mild and moderate patients.

(a-c) Bar charts show the frequency of (a) cTfh cells, (b) activated cTfh cells and (c) SARS-CoV-2 spike and RBD-specific cTfh cells with mean in COVID-19 patients with acute disease according to weeks after symptom onset. Bar charts show the frequency of (d) SARS-CoV-2 spike and RBD-specific, (e) activated CXCR5− memory CD4 T cells (non-cTfh cells) with mean in COVID-19 patients with acute disease according to weeks after symptom onset. (f) Bar charts show the avidity index of plasma IgG during acute disease against SARS-CoV-2 spike across peak disease severity over weeks after symptom onset with mean. (g) Spearman correlation for frequency of activated and virus-specific cTfh during acute disease versus avidity index of plasma IgG during acute disease. (a-g) 9, 22 and 33 individual samples from 9 mild, 14 moderate and 18 severe patients respectively were analysed. (h, j) Bar charts show the (h) neutralization IC100 and (j) anti-spike IgG neutralization potency index of COVID-19 patient plasma samples across peak disease severity over weeks after symptom onset. (i) Spearman correlation for frequency of activated and virus-specific cTfh during acute disease versus plasma neutralization IC100 during acute disease. (h-j) 9, 22 and 31 individual samples from 9 mild, 14 moderate and 17 severe patients respectively were analysed. Dots are individual samples color-coded according to peak disease severity. Dotted lines show the mean frequency with 95% Cl (grey area) of healthy controls. X axis shows number of patients in each bar. Dots from same patient are linked with line in each bar. Time-period specific differences between groups in were calculated using by using time-period specific subsets of the data. The graphical presentations of the different outcomes were based on a GEE model with time modelled using a restricted cubic spline with knots at 0, 14, 21, 28 and 53 days. Statistically significant differences were assessed at p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. (g, i) Only 1 individual sample from each patient was analysed for Spearman correlation during acute disease. For patients with longitudinal acute samples, data from the earliest sample was involved as representative in Spearman correlation analysis.

During early infection less than 2 weeks after symptom onset, frequencies of activated non-cTfh cells were even higher in severe patients than in individuals who maintained/developed mild or moderate COVID-19 (Figure 5e). We also found that the severe COVID-19 patients with delayed generation of activated and virus-specific cTfh cells, showed no significant difference in age, gender or CCI, but higher BMI compared with mild and moderate patients (Table 3).

Delayed appearance of virus-specific cTfh cells is associated with delayed generation of high avidity and neutralizing plasma SARS-CoV-2 antibodies

To understand the potential functional consequences of delayed appearance of activated and virus-specific cTfh cells, we assessed the avidity and neutralizing capacity of plasma antibodies against SARS-CoV-2 from COVID-19 patients during acute disease. In line with the cTfh data, we found that in individuals who already displayed or later developed severe disease, the avidity index of plasma IgG antibodies against spike protein (Figure 5f and Supplementary Figure 6a) and the plasma neutralization IC₁₀₀ against SARS-CoV-2 (isolate SARS-CoV-2/human/SWE/01/2020) (Figure 5h) were significantly lower than in patients who maintained or developed mild or moderate COVID-19 within 2 weeks after symptom onset. However, the antibody avidity index and neutralizing capacity increased as disease progressed and reached similar or higher levels than moderate patients after 4 weeks of symptom onset (Figure 5f, h and Supplementary Figure 6b). The frequency of activated and SARS-CoV-2 spike-specific cTfh cells correlated strongly with the avidity index of plasma IgG antibodies (Figure 5g) and plasma neutralization IC₁₀₀ (Figure 5i). Though the titers of plasma IgA and IgG antibodies against SARS-CoV-2 spike and RBD in severe patients showed similar or even higher level compared with mild COVID-19 patients during early infection (Supplementary Figure 7a-b), the plasma neutralization potency (calculated as IC₁₀₀ divided by antibody titers) in severe patients was significantly lower than mild and moderate patients (Figure 5j). As failure to achieve high avidity and neutralizing antibodies has been shown to result in a lack of protective immunity against SARS-CoV-2 infection ³⁴, our study suggests that impaired generation of functional virus-specific cTfh cells delays the production of protective antibodies to combat the infection at an early stage and thereby enables progression to more severe COVID-19 disease. In summary, delayed generation of activated and SARS-CoV-2-specific cTfh resulted in a delayed production of high-quality antibodies for protection, which may consequently worsen COVID-19 disease progression.

Study design and patient inclusion

COVID-19 patients confirmed by SARS-CoV-2 PCR test were enrolled at the Karolinska University Hospital and Haga Outpatient Clinic (Haga Närakut), Stockholm, Sweden. Additionally, patients with mild disease were included by recruiting household contacts who were SARS-CoV-2 PCR positive. In total 147 COVID-19 adult patients were recruited as previously reported ^33,52. For this study, we selected patients with non-fatal outcome and available biobanked longitudinal acute and convalescent samples, and excluded patients with autoimmune disease or haematological malignancies. Consequently, 41 COVID-19 patients were included in this study. These patients were subsequently sampled at approximately 3 (n=39 patients) and 8 (n=35 patients) months after recovery. Blood samples from 20 age and gender matched healthy controls (HCs) recruited prior to the pandemic were also included (Figure 1a). Clinical characteristics were compared between the COVID-19 patient cohort and HCs (Table 1). The total burden of comorbidities was assessed using the Charlson Comorbidity index (CCI) ⁵³. Disease severity was assessed daily in admitted patients, according to the respiratory domain of the sequential organ failure assessment (SOFA) score ⁵⁴, with additional levels for non-admitted patients as mild cases (Figure 1b). Patients were grouped depending on their peak disease severity. Medical records from grouped patients across disease severity were analysed (Table 2). We included the vast majority of our study participants (9 mild, 14 moderate and 18 severe) in March-May 2020, when corticosteroid use was still not common practice in Stockholm, Sweden. Therefore, only 3 COVID-19 patients were treated with cortisone (Table 2), and one was sampled before cortisone was administered. For functional co-culture experiments, we recruited new patients (4 mild and 4 severe) in December 2020 – March 2021 that did not receive corticosteroid treatment during the sampling period. However, two patients were sampled 26 and 37 days after corticosteroid treatment was concluded. None of the patients in this study received IL-6 inhibitors (tocilizumab) or IL-1 inhibitors during the study/sampling period.

Flow cytometry

Staining for subsets of cTfh cells and plasmablast in PBMCs was performed on cryopreserved samples based on our earlier protocols ^55,56 with modifications. Cells were stained using Live/Dead Blue (Invitrogen) or Live/Dead Aqua (Invitrogen) first and then incubated with human FcR blocking reagent (Miltenyi Biotec) and stained with appropriate combination of fluorescently labelled monoclonal antibodies (Supplementary Table 1-4) for 20 minutes at 4°C. Cells were washed with PBS and fixed with 1% paraformaldehyde. Samples were acquired using LSRFortessa flow cytometer (BD). Data were analysed using FlowJo version 10 (TreeStar).

Cytokine and chemokine analysis

Concentration of cytokines in the supernatants from PBMCs stimulation assay and cTfh-B cell co-culture assay was determined by Custom-made Luminex® assay (LXSAHM, R&D Systems), including IL-21, IFNγ, IL-4, IL-17 and TNF based on the manufacturer’s protocol. Briefly, supernatants were incubated with the microparticle cocktail on a shaker (800 rpm) for 2 hours at room temperature (RT). Then wells were washed and incubated with biotin-antibody cocktail on a shaker (800 rpm) for 1 hour at RT. Next wells were washed and incubated with Streptavidin-PE on a shaker (800 rpm) for 0.5 hour at RT. Subsequently, wells were washed and diluted in wash buffer and the results were generated by Bio-Plex 200 analyzer (BIO-RAD).

Plasma chemokine CXCL13 was analysed using aptamer-based SOMAscan ® proteomic discovery platform v4.1 (SOMAlogic Inc., Boulder CO), according to the manufacturer’s protocols ⁵⁷. The discovery platform allows detection of approximately 7,000 protein analytes using modified single stranded DNA-based protein affinity reagents referred as SOMAmers (Slow Off-rate Modified Aptamers). The data generated from this assay passed through multiple standardization and normalization steps including adaptive normalization by maximum likelihood to minimize intra- and inter-assay variation. The quantitative levels of protein analytes were presented as relative fluorescence unit (RFU). For this paper, only CXCL13 data were included.

Plasma cytokines and chemokines were also tested by Olink Proteomics assay (92-biomarker Inflammation panel) performed based on the manufactureŕs instructions ⁵⁸. Briefly, DNA oligonucleotides labelled antibodies combine with target antigen and oligonucleotides were hybridized and extended by DNA polymerase. Then protein expression levels were determined by high-throughput real-time PCR and presented as normalized protein expression (NPX) values. Values were calculated from inverted Ct values, with a high NPX value corresponding to a high protein concentration. Intensity normalization of data was performed according to the manufacturer’s protocol, to minimized intra- and interassay variation.

Detection of SARS-CoV-2-specific cTfh cells

Recombinant SARS-CoV-2 spike and receptor binding domain (RBD) proteins were received through the global health-vaccine accelerator platforms (GH-VAP) funded by the Bill & Melinda Gates Foundation. Cryopreserved PBMCs were thawed and rested for 2h at incubator. Then cells were cultured in 96-well U-bottomed plates (0.5×10⁶ cells per well) and exposed to 5 μg/mL of protein (SARS-CoV-2 spike, SARS-CoV-2 RBD and BSA), or 5 μg/mL of staphylococcal enterotoxin B (SEB) for 20 h. After stimulation, cells were collected and analysed by flow cytometry as described above; culture supernatants were harvested to determine concentrations of cytokines by Luminex® assay.

Serology

The titers of plasma IgA and IgG binding against SARS-CoV-2 spike trimer or receptor binding domain (RBD) monomer were determined by enzyme-linked immunosorbent assay (ELISA). Recombinant SARS-CoV-2 spike and RBD proteins were received through the global health-vaccine accelerator platforms (GH-VAP) funded by the Bill & Melinda Gates Foundation. Briefly, 96-half well plates were coated with 50ng/well of the respective protein. Plates were incubated with duplicate dilution (1:20) of each plasma sample at ambient temperature for 2 hours. Detection was performed with a goat anti-human IgG HRP-conjugated secondary antibody from BD Biosciences (Clone G18-145) followed by incubation with TMB substrate (BioLegend) which was stopped with a 1M solution of H₂SO₄. Absorbance was read at 450nm + 550nm (background correction) using an ELISA reader. Data are represented as the mean OD value of the 2 duplicates.

Plasma antibody avidity were tested for by an anti-SARS-CoV-2 ELISA ⁵⁵. Briefly, 96-half well plates were coated with 50ng/well of the recombinant SARS-CoV-2 spike protein. Plates were incubated with 5-fold dilution series of each plasma sample at ambient temperature for 2 hours and then washed with 0.1% Tween-20/PBS washing buffer. To determine the relative avidity index, two rows of microplate wells next to each other were used for each subject. In one row wells were incubated with PBS and in the other row wells were incubated with 1.5M solution of sodium thiocyanate for 10 minutes at ambient temperature, followed by washing with washing buffer. The sodium thiocyanate treatment leads to the detachment of low-avidity antibodies from the antigen. Detection was performed with a goat anti-human IgG HRP-conjugated secondary antibody from BD Biosciences (Clone G18-145) followed by incubation with TMB substrate (BioLegend) which was stopped with a 1M solution of H₂SO₄. Absorbance was read at 450nm + 570nm (background correction) using an ELISA reader and the half maximal effective concentration (EC₅₀) was calculated using GraphPad Prism 9. The relative avidity index was calculated from the ratio of the EC₅₀ with and without sodium thiocyanate treatment and is expressed as percentage.

Neutralization of replicating SARS-CoV-2 in plasma samples from COVID-19 patients was as described previously ^59,60. Briefly, plasma from COVID-19 patients was 3-fold serially diluted, mixed with SARS-CoV-2 (isolate SARS-CoV-2/human/SWE/01/2020, https://www-ncbi-nlm-nih-gov.proxy.kib.ki.se/nuccore/MT093571), incubated for 1 hour and added, in duplicates, to confluent Vero E6 cells in 96-well plates. After 5 days of incubation, wells were inspected for signs of cytopathic effects (CPE) by optical microscopy. Each well was scored as either neutralizing (if no signs of CPE was observed) or non-neutralizing (if any CPE was observed). The arithmetic mean neutralization titer of the reciprocals of the highest neutralizing dilutions from the two duplicates for each sample was then calculated to determine the IC100.

cTfh functional assay

cTfh, non-cTfh, naïve and memory B cells were sorted from frozen PBMCs from three severe and mild COVID-19 patients with acute disease respectively and three healthy donors, using FACS Aria Fusion (BD) with a 100μm nozzle (Supplementary figure 2 and Supplementary table). Sorted cTfh or non-cTfh cells (5×10⁴ cells per well) were co-cultured with autologous memory B cells (5×10⁴ cells per well) for 6 days and with autologous naïve B cells (5×10⁴ cells per well) for 9 days in complete RPMI 1640 + 10% FCS in the presence of SEB (1μg/mL) in 96-well U-bottomed plates. Culture supernatants were harvested at day 2 to measure cytokines by Luminex® assay. After 6 and 9 days of culturing, cells were harvested to determine B cell count and differentiation by flow cytometry as described above, and culture supernatants were collected to test IgA and IgG concentrations by ELISA.